Mackenzie Financial Corp Invests $35,000 in Kezar Life Sciences, Inc. (NASDAQ:KZR)

Mackenzie Financial Corp acquired a new stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 58,709 shares of the company’s stock, valued at approximately $35,000. Mackenzie Financial Corp owned 0.08% of Kezar Life Sciences as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Ikarian Capital LLC grew its position in shares of Kezar Life Sciences by 1.8% in the first quarter. Ikarian Capital LLC now owns 868,992 shares of the company’s stock valued at $783,000 after purchasing an additional 15,601 shares in the last quarter. Fidelis Capital Partners LLC bought a new stake in shares of Kezar Life Sciences during the first quarter valued at about $25,000. Vanguard Group Inc. lifted its holdings in shares of Kezar Life Sciences by 1.0% in the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock worth $2,790,000 after buying an additional 30,740 shares in the last quarter. Acadian Asset Management LLC grew its stake in Kezar Life Sciences by 3.6% during the second quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock valued at $1,112,000 after acquiring an additional 64,356 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Kezar Life Sciences by 35.4% during the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after acquiring an additional 71,543 shares during the period. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Stock Performance

Kezar Life Sciences stock opened at $0.74 on Wednesday. The firm’s fifty day moving average price is $0.62 and its 200-day moving average price is $0.69. Kezar Life Sciences, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $1.14. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 9.58. The stock has a market cap of $53.87 million, a P/E ratio of -0.53 and a beta of 0.21.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, equities research analysts expect that Kezar Life Sciences, Inc. will post -1.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a research report on Wednesday, October 2nd.

Kezar Life Sciences Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.